{"id":"W4387449548","doi":"10.1093/oncolo/oyad254","title":"Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy and Docetaxel in Black Patients From the Randomized ARASENS Trial","year":2023,"lang":"en","type":"article","venue":"The Oncologist","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Institute on Minority Health and Health Disparities; Astellas Pharma; Foundation Medicine; Bayer HealthCare; Pfizer; American Association for Cancer Research; Invitae; Eli Lilly and Company; Lantheus Medical Imaging","keywords":"Docetaxel; Medicine; Placebo; Internal medicine; Clinical endpoint; Androgen deprivation therapy; Prostate cancer; Population; Adverse effect; Enzalutamide; Oncology; Randomized controlled trial; Chemotherapy; Cancer; Androgen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002318414,0.001095666,0.00206672,0.0002909983,0.0003960997,0.0007101775,0.0004750721,0.0009468483,0.003845754],"category_scores_gemma":[0.002279479,0.0003774349,0.002176615,0.0002964485,0.0006470066,0.0004515178,0.0005463944,0.001357827,0.0003868869],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006119874,"about_ca_system_score_gemma":0.000905393,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007117816,"about_ca_topic_score_gemma":0.001820368,"domain_scores_codex":[0.9987563,0.0009274539,0.00005198901,0.0001074245,0.00007302221,0.00008378291],"domain_scores_gemma":[0.9989402,0.000212234,0.0003792527,0.000063889,0.00008373515,0.0003206611],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9687237,0.001785347,0.005489637,0.000472652,0.002523739,0.00006705736,0.00006321604,0.0003461511,0.002638959,0.0001533103,0.001250637,0.01648572],"study_design_scores_gemma":[0.9214224,0.05179602,0.01818836,0.0001630243,0.003922761,0.000152412,0.00006408353,0.0007471186,0.0006374278,0.0004526592,0.002420706,0.00003298713],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9886022,0.006908881,0.000236176,0.001169737,0.0002655183,0.0006388631,0.0006814637,0.00002278415,0.001474401],"genre_scores_gemma":[0.9914047,0.002973975,0.0007539802,0.001206358,0.0004141277,0.001016504,0.00109892,0.00001307481,0.001118414],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003845754,"threshold_uncertainty_score":0.0128653,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04382962024491794,"score_gpt":0.3280183482990482,"score_spread":0.2841887280541303,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}